Biovie Inc (BIVI)

$1.19 -0.05 (-4.03%)
Market Cap 8.60M
Revenue (ttm) 0.00
Net Income (ttm) -17.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 119,700
Avg Vol 98,296
Day's Range N/A - N/A
Shares Out 7.54M
Stochastic %K 42%
Beta 0.36
Analysts Sell
Price Target $12.00

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 775 888 3162
Address:
680 W. Nye Lane, Suite 204, Carson City, United States
Rod75b15
Rod75b15 Feb. 2 at 9:37 PM
$BIVI
0 · Reply
Sensore
Sensore Feb. 2 at 8:56 PM
$BIVI ..
0 · Reply
Thorilium
Thorilium Jan. 29 at 4:13 PM
$BIVI still downwards? Time to give up not?
0 · Reply
peepthestamp
peepthestamp Jan. 29 at 1:26 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jan. 26 at 3:19 PM
$BIVI dirty gyps, fountain of youth scam bs
0 · Reply
Mrzoppa
Mrzoppa Jan. 15 at 9:51 PM
$BIVI started position 1.18
1 · Reply
GridMaestro
GridMaestro Jan. 15 at 9:44 PM
$BIVI 🧐🧐😉
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 11:56 AM
$BIVI RSI: 43.06, MACD: -0.0577 Vol: 0.09, MA20: 1.31, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TJ12000
TJ12000 Jan. 14 at 6:42 PM
$BIVI gypsy greaseball wannabe ceo
0 · Reply
TJ12000
TJ12000 Jan. 9 at 8:48 PM
$BIVI for those that think this scam won’t split again, u need ur head examined #blatant gypsy scam
0 · Reply
Latest News on BIVI
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 2:05 PM EST - 5 weeks ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript

Dec 9, 2025, 9:27 PM EST - 2 months ago

BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 19, 2025, 8:00 AM EST - 2 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 8:20 AM EDT - 3 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioVie Inc. - Special Call

Oct 8, 2025, 6:56 PM EDT - 4 months ago

BioVie Inc. - Special Call

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 26, 2025, 8:00 AM EDT - 4 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Aug 13, 2025, 4:05 PM EDT - 6 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 7, 2025, 8:43 PM EDT - 6 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Jul 24, 2025, 8:00 AM EDT - 6 months ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 7 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 26, 2025, 8:00 AM EDT - 7 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 24, 2025, 4:05 PM EDT - 8 months ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 14, 2025, 7:30 AM EDT - 9 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Mar 27, 2025, 8:00 AM EDT - 11 months ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation

Jan 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect

Jan 22, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out

Jan 19, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 1 year ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect

Jan 5, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation

Jan 2, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out

Dec 24, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out

Dec 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect

Dec 18, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 15, 2024, 10:00 AM EST - 1 year ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

Dec 11, 2024, 2:00 PM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

BioVie Inc. Announces Closing of Public Offering

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

Crude Oil Gains Over 1%; BioVie Shares Plunge

Sep 24, 2024, 2:08 PM EDT - 1 year ago

Crude Oil Gains Over 1%; BioVie Shares Plunge

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 27, 2024, 8:45 AM EDT - 1 year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 8, 2024, 6:00 AM EDT - 1 year ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

BioVie Inc. Announces Reverse Stock Split

Aug 6, 2024, 4:40 PM EDT - 1 year ago

BioVie Inc. Announces Reverse Stock Split

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 5, 2024, 9:00 AM EDT - 1 year ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 21, 2024, 9:00 AM EDT - 1 year ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 20, 2024, 8:00 AM EDT - 1 year ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Jun 12, 2024, 8:24 AM EDT - 1 year ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

May 22, 2024, 8:00 AM EDT - 1 year ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Apr 29, 2024, 8:00 AM EDT - 1 year ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Apr 25, 2024, 8:00 AM EDT - 1 year ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Rod75b15
Rod75b15 Feb. 2 at 9:37 PM
$BIVI
0 · Reply
Sensore
Sensore Feb. 2 at 8:56 PM
$BIVI ..
0 · Reply
Thorilium
Thorilium Jan. 29 at 4:13 PM
$BIVI still downwards? Time to give up not?
0 · Reply
peepthestamp
peepthestamp Jan. 29 at 1:26 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jan. 26 at 3:19 PM
$BIVI dirty gyps, fountain of youth scam bs
0 · Reply
Mrzoppa
Mrzoppa Jan. 15 at 9:51 PM
$BIVI started position 1.18
1 · Reply
GridMaestro
GridMaestro Jan. 15 at 9:44 PM
$BIVI 🧐🧐😉
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 11:56 AM
$BIVI RSI: 43.06, MACD: -0.0577 Vol: 0.09, MA20: 1.31, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TJ12000
TJ12000 Jan. 14 at 6:42 PM
$BIVI gypsy greaseball wannabe ceo
0 · Reply
TJ12000
TJ12000 Jan. 9 at 8:48 PM
$BIVI for those that think this scam won’t split again, u need ur head examined #blatant gypsy scam
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 8:21 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jan. 8 at 5:35 PM
$BIVI gypsy scam
0 · Reply
Tradebait88
Tradebait88 Jan. 8 at 1:40 PM
$BIVI If P2 hits, this goes extremely high, like bonkers. The reward is worth the risk down here.
1 · Reply
Rod75b15
Rod75b15 Jan. 8 at 1:19 PM
$BIVI SUNRISE-PD enrolled individuals ages 41 to 80 who were diagnosed with PD within the past four years and had not been treated with carbidopa/levodopa. BioVie supported enrollment through outreach and awareness efforts with the support of leading advocacy organizations in the PD field, including The Michael J. Fox Foundation, Davis Phinney Foundation, and the Parkinson’s Foundation.
0 · Reply
Rod75b15
Rod75b15 Jan. 8 at 1:18 PM
$BIVI https://finance.yahoo.com/news/biovie-completes-enrollment-phase-2-130000612.html
0 · Reply
TJ12000
TJ12000 Jan. 7 at 8:03 AM
$BIVI Kong u deserve that bald head u dirty gypsy mofo
0 · Reply
Rod75b15
Rod75b15 Jan. 2 at 5:38 PM
$BIVI
0 · Reply
History101
History101 Dec. 31 at 6:51 PM
$BIVI not good news for BIVI: https://finance.yahoo.com/m/9aa9dead-a87f-3e90-8141-6121df73539b/axsome-therapeutics-stock.html
0 · Reply
Thorilium
Thorilium Dec. 31 at 6:56 AM
$BIVI like I told, below 1 and will drop somewhat more until data is expected
0 · Reply
TJ12000
TJ12000 Dec. 30 at 7:25 PM
$BIVI gypsy scam molecule, bring them lawsuits
0 · Reply
Tradebait88
Tradebait88 Dec. 30 at 2:33 PM
$BIVI should make a run going into p2 data, good entry
0 · Reply
Thorilium
Thorilium Dec. 30 at 12:54 AM
$BIVI going below 1 again, how many reverse splits over 2026 This stock is a waiste of money
0 · Reply